NCT05792930

Brief Summary

This research program is aimed to develop a integrative psychotherapy (including CBT and biofeedback therapy) and to examine its efficacy on treatment of somatic symptom disorder. The study design is a randomized controlled trial with waiting list control. Scores of Patient Health Questionniare-15 and Health Anxiety Questionnaire are the primary endpoints.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
60

participants targeted

Target at P25-P50 for not_applicable

Timeline
2mo left

Started Jul 2023

Typical duration for not_applicable

Geographic Reach
1 country

1 active site

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress95%
Jul 2023Jun 2026

First Submitted

Initial submission to the registry

March 20, 2023

Completed
11 days until next milestone

First Posted

Study publicly available on registry

March 31, 2023

Completed
3 months until next milestone

Study Start

First participant enrolled

July 11, 2023

Completed
3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 30, 2026

Expected
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

June 30, 2026

Last Updated

December 19, 2025

Status Verified

December 1, 2025

Enrollment Period

3 years

First QC Date

March 20, 2023

Last Update Submit

December 17, 2025

Conditions

Keywords

somatic symptom disordercognitive behavioral therapybiofeedback therapysomatic distresshealth anxiety

Outcome Measures

Primary Outcomes (2)

  • Scores of Patient Health Questionnaire-15 (PHQ-15)

    Measurement of somatic distress. Score range is 0 to 30; higher score means more severe somatic distress

    Week 12 (comparing with the data in week 0)

  • Scores of Health Anxiety Questionnaire (HAQ)

    Measurement of health anxiety. Score range is 0 to 63; higher score means more severe health anxiety

    Week 12 (comparing with the data in week 0)

Secondary Outcomes (5)

  • Scores of Beck Depression Inventory-II (BDI-II)

    Week 12 (comparing with the data in week 0)

  • Scores of Beck Anxiety Inventory (BAI)

    Week 12 (comparing with the data in week 0)

  • Scores of Cognitions About Body and Health Questionnaire (CABAH)

    Week 12 (comparing with the data in week 0)

  • Heart rate variability

    Week 12 (comparing with the data in week 0)

  • Skin conductance

    Week 12 (comparing with the data in week 0)

Study Arms (2)

Experimental Group

EXPERIMENTAL

The experimental group will receive cognitive-behavioral therapy (CBT) and biofeedback therapy.

Behavioral: cognitive-behavioral therapy and biofeedback therapy

Control Group

NO INTERVENTION

The design of control group is waiting list control; their data will be collected without intervention during the observation period. After the observation period, psychotherapy (CBT and biofeedback, the same as intervention) will be arranged.

Interventions

Complete eight sessions of cognitive-behavioral therapy and biofeedback therapy within three months.

Experimental Group

Eligibility Criteria

Age20 Years - 70 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Patient with somatic symptom disorder (confirmed by psychiatrists)

You may not qualify if:

  • The age is younger than 20 or older than 70 years
  • Having psychotic symptoms or cognitive impairment
  • Having a potentially lethal illness
  • Cannot read the questionnaires by oneself

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Department of Psychiatry, National Taiwan University Hospital Yunlin Branch

Yunlin, 640, Taiwan

RECRUITING

MeSH Terms

Interventions

Cognitive Behavioral TherapyBiofeedback, Psychology

Intervention Hierarchy (Ancestors)

Behavior TherapyPsychotherapyBehavioral Disciplines and ActivitiesMind-Body TherapiesComplementary TherapiesTherapeuticsFeedback, Psychological

Study Officials

  • Wei-Lieh Huang, MD, PhD

    National Taiwan University Hospital

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Wei-Lieh Huang, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

March 20, 2023

First Posted

March 31, 2023

Study Start

July 11, 2023

Primary Completion (Estimated)

June 30, 2026

Study Completion (Estimated)

June 30, 2026

Last Updated

December 19, 2025

Record last verified: 2025-12

Locations